Artixio

Regulatory Intelligence, Monitoring and Risk Analysis Tool

Global Clinical and Post Market Safety and Pharmacovigilance Services for Pharmaceutical and Biotech Industry

Regulatory Intelligence, Monitoring and Risk Analysis Tool

Access regulatory guidelines, guidance in key markets worldwide to compliment your ongoing regulatory affairs department for new product clinical development, product registration, product launch, pricing and reimbursement and post approval lifecycle maintenance. QuriousRI, Artixio’s regulatory intelligence software tool, comprehensively covers all applicable regulatory guidelines from health authorities and tracks regulatory updates in real time.

QuriousRI – Highlights

Key Features

Step Feature Description
1 Engage All Stakeholders Bring all key stakeholders across teams onto one unified platform.
2 Setup Tracking Dashboard Configure dashboards by Country, Therapy Area, Key Functions, and Products of Interest.
3 Notification Frequency Select how often you want updates and receive email alerts accordingly.
4 Review Updates Get summarized update headlines and brief reviews prepared by Artixio’s expert team.
5 Risk Impact Analysis Analyze potential impacts of new updates on your products, portfolio, or documentation across markets.

Set Your Frequency of Updates

Receive email alerts on daily, weekly, fortnightly or monthly basis.

Dashboards

  • Review Historical Updates and Related Guidelines
  • Analytics Dashboard covering Regions, Countries, Update Types, Functions Impacted and more
  • Assess Regulatory Risks based on Historical and New Updates to plan for potential future risk mitigation plans

Risk Impact Analysis

Assess Products and Licenses that may be at Risk due to Changing Regulations

Our Risk Analysis module covers deep-analysis of regulatory update on products and documents across product categories, therapy areas and regulatory functions, led by our in-country experienced team of Regulatory specialists.

Identify Key Functions That can be potentially at Risk including, Labeling, Artwork and Packaging, Patient Communication, Manufacturing, Quality, Clinical, Safety, Import and Customs, Administrative, Environment and other areas.

Risk Scoring based on Scale of the Risk across Product Classes, Procedure and Process Level, Functional areas and document. Risk assessment with variable degree of impacts, including,
  • No impact
  • Administrative Information, Internal Changes Possible
  • Minor administrative changes possibly leading to some Health Authority (HA) submissions
  • Major technical/Admin changes leading to Health Authority (HA) submissions or Change in Regulatory Strategy 

Wide Industry and Therapy Areas Coverage

  • Pharmaceuticals, Biologics, Biosimilars, Cell and Gene Therapy, Radiopharmaceuticals, Cosmetics, Supplements, Nutraceuticals and Food.
  • Oncology, Rare Diseases, Cardiovascular, Metabolic, Neurology, Infectious Diseases, Inflammation, Pain, Allergy and others.

Integrated Regulatory Strategy, Planning and Gap Analysis – QuriousRI-GP

Our tracking and monitoring platform is integrated with the QuriousRI-GP, a one of its kind Regulatory Strategy, Planning and Gap Analysis simulation platform to fast track your strategy and planning process for key markets worldwide.

Expert Regulatory Team at Speed Dial

Artixio’s regulatory experts are based in key markets worldwide bringing decades of experience working on successful product approvals (new chemical entities, generics, biologics, biosimilars, radiopharmaceuticals, cell and gene therapy and others). You can access our team for specific questions you may have related to the regulations in a country or a new regulatory update.

Why Artixio For Pharmacovigilance Services?

FAQs

1. How can QuriousRI help my team with regulatory intelligence?
QuriousRI helps regulatory teams access regulations, guidelines from health authorities worldwide across product categories. It also helps tracking latest updates coupled with expert written summaries to stay ahead of new changes that may potentially impact their products (under development or marketed) in global markets. QuriousRI also offers deep-dive impact analysis on therapy areas, products or processes in general that can help regulatory teams assess the impact and potential risk of new regulatory update on their portfolio.
Simply write to info@artixio.com and our team will assist you with the process.
Artixio leverages our in-house artificial intelligence engineering, data sciences team track global updates in real time automatically. Our regulatory experts then review the updates to prepare a summary and perform further Risk Analysis.

Still Have Questions ?

Get expert answers tailored to your needs.

Specialized Pharmacovigilance
Services Across Multiple Industries

Pharmaceuticals

MedTech

Cosmetics

Nutrition

Biologics

Veterinary

Expert Regulatory Services To Streamline Compliance

Regulatory Intelligence & Strategy
Medical & Technical Writing
Publishing & Submission
Product Registration
Investigation New Drug Application (IND)
New Drug Application (NDA)
Post Approval Lifecycle Maintenance
Artwork and Label Review
Ad Promo Review

Regulatory Affairs Across Multiple Countries

India

Singapore

Mexico

Brazil

Vietnam

Malaysia

Argentina

Colombia

Taiwan

China

European

Thailand

Indonesia

Philippines

USA

Japan

Qatar

South Korea

Insights from Artixio - Tips & Articles

CDSCO Simplifies Subsequent Importer Process for Medical Devices & IVDs

CDSCO Simplifies Subsequent Importer

India’s regulatory authority, the Central Drugs Standard Control Organization (CDSCO), has published an important...

October 3, 2025
AI For Monitoring Regulatory Updates In Pharmaceuticals & Medical Devices

AI For Monitoring Regulatory

Regulations in pharma and medical devices don’t stand still. They change as new technologies...

September 30, 2025
Case Study: AI for Global Product Quality Violations & Tracking Identified Counterfeit Medicines

Case Study: AI for

Globally, substandard or falsified medicines impact millions of lives every year, including hundreds of...

September 29, 2025